Cesar de Jesus Tovar Jacome

Dr. Cesar de Jesus Tovar Jacome

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2025 in Genes
Verified
Journal Article
Open access
PDF file
MJMaria Renee Jimenez
Maria Renee Jimenez
CJCesar de Jesus Tovar Jacome
Cesar de Jesus Tovar Jacome
ARALEJANDRA PALACIOS RAMIREZ
ALEJANDRA PALACIOS RAMIREZ
Martha GallegosMartha Gallegos
Martha Gallegos
TMTeresa Giovanna María Aguilar Macedo
Teresa Giovanna María Aguilar Macedo
MRMonica Alejandra Rosales-Reynoso
Monica Alejandra Rosales-Reynoso
Background/Objectives: Breast cancer (BC) is a multifactorial disease, with genetic alterations in cell proliferation and migration pathways being significant risk factors. This study examines the association between three variants in the BIRC5 gene (rs8073069, rs17878467, and rs9904341) and breast cancer (BC) susceptibility. Methods: Peripheral blood DNA samples were collected from 423 women (221 BC patients and 202 healthy controls). Genotyping was performed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) methodology. Associations were calculated using odds ratios (OR), with p-values adjusted by the Bonferroni test (significance at p ≤ 0.016). In silico analyses were conducted to predict the functional impact of the analyzed variants. Results: Patients carrying the C/C genotype for the rs8073069 variant showed increased susceptibility to BC with early TNM (tumor-node-metastasis classification) stage and Luminal A subtype (OR > 2.00; p ≤ 0.004). For the rs17878467 variant, patients with the C/T or T/T genotype exhibited a higher susceptibility to developing breast cancer (BC), particularly at early TNM stages or with a histological lobular type (OR > 2.00; p ≤ 0.012). Regarding the rs9904341 variant, patients with the G/C or C/C genotype had a higher susceptibility to breast cancer. Notably, G/C genotype carriers with Luminal A and B subtypes, and C/C genotype carriers who had TNM stages II and III, and Luminal A, Luminal B, and HER2 subtypes demonstrated increased risk (OR > 2.00; p ≤ 0.009). The C-T-C haplotype (rs8073069–rs17878467–rs9904341) was significantly associated with BC (OR = 4.20; 95% CI = 2.38–7.41; p ≤ 0.001). In silico analysis using CADD indicated a low probability of deleterious effects. Conclusions: The results suggest that the rs8073069, rs17878467, and rs9904341 variants in BIRC5 have a significant influence on breast cancer susceptibility.

27 November 2024 in Cellular and Molecular Biology
Verified
Journal Article
Open access
ASAnilú Margarita Saucedo-Sariñana
Anilú Margarita Saucedo-Sariñana
YTYuri Giovanna Vanessa Trujillo-Fernández
Yuri Giovanna Vanessa Trujillo-Fernández
CJClara Ibet Juárez-Vázquez
Clara Ibet Juárez-Vázquez
MGMiriam Yadira Godínez-Rodríguez
Miriam Yadira Godínez-Rodríguez
CJCesar de Jesus Tovar Jacome
Cesar de Jesus Tovar Jacome
MRMonica Alejandra Rosales-Reynoso
Monica Alejandra Rosales-Reynoso
Connective tissue growth factor (CTGF) and Caspase 8 (CASP8) have been implicated in cancer development and progression. Variants such as CASP8 rs3834129 (-652 6N I/D) and CTGF rs6918698 (-945 C>G) have been associated with several cancers, although their association is still debated between populations. This study investigates the possible association between the CASP8 rs3834129 and CTGF rs6918698 variants with colorectal cancer (CRC) in Mexican patients. Genomic DNA was extracted from 250 CRC patients and 250 control subjects. The identification of CASP8 and CTGF variants was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. The association was determined by the odds ratio (OR) analysis and P values were adjusted by the Bonferroni correction. Patients carrying the D/D genotype for the CASP8 rs3834129 variant exhibited an increased susceptibility to CRC (P = 0.012). The D/D genotype was associated with older 50-year-old patients (P = 0.006). In addition, this same D/D genotype was associated with TNM II stage (P = 0.013) and rectal localization (P = 0.023). Additionally, patients carrying the G/G genotype for the CTGF rs6918698 variant showed a decreased susceptibility to CRC (P = 0.009), and in the sex stratification, this gene has protective role in males (P = 0.008). This same genotype was associated with decreased susceptibility to early TNM stages (I+II) (P = 0.023) and right-sided colon tumor localization (P = 0.002). There was no association between response to treatment and the variants analyzed. Our findings suggest that the CASP8 rs3834129 and CTGF rs6918698 variants have a significant impact on the development of CRC.

15 February 2025 in Genes
Verified
Journal Article
Open access
PDF file
CJCesar de Jesus Tovar Jacome
Cesar de Jesus Tovar Jacome
CJClara Ibet Juárez-Vázquez
Clara Ibet Juárez-Vázquez
Martha GallegosMartha Gallegos
Martha Gallegos
JGJOSÉ ELÍAS GARCÍA-ORTÍZ
JOSÉ ELÍAS GARCÍA-ORTÍZ
MMMaría Eugenia Marín-Contreras
María Eugenia Marín-Contreras
MRMonica Alejandra Rosales-Reynoso
Monica Alejandra Rosales-Reynoso
Background/Objectives: Colorectal cancer (CRC) is the second leading cause of cancer death worldwide. Variants in genes that regulate processes such as apoptosis and angiogenesis play a significant role in CRC. The objective of this study is to investigate the possible association between RASSF1 (rs2073498), SERPINE1 (rs1799889), EFNA1 (rs12904), and RAD51 (rs1801320) variants and clinicopathological characteristics of Mexican patients with CRC. Methods: DNA of peripheral blood samples was obtained from 631 individuals (349 patients and 282 control individuals). The RASSF1 (rs2073498), SERPINE1 (rs1799889), EFNA1 (rs12904), and RAD51 (rs1801320) variants were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The association was calculated using the odds ratio (OR) test. p-values were adjusted by the Bonferroni test (0.0125). In silico analysis programs, including Combined Annotation Dependent Depletion (CADD), Polymorphism Phenotyping-2 (PolyPhen-2), and Gene Expression Profiling Interactive Analysis (GEPIA), were conducted to predict the functional impact of these variants. Results: Patients carrying the G/A genotype of the RASSF1 (rs2073498) variant showed an association with CRC characteristics, including TNM stages and tumor location (OR > 2.5, p = 0.001). Regarding the SERPINE1 (rs1799889) variant, patients carrying the 5G/4G genotype showed an association between TNM stages and tumor location in the rectum (OR > 1.5, p ≤ 0.05). Patients with the G/G genotype for the EFNA1 (rs12904) variant showed an association with TNM stages and rectal tumor location (OR > 2.0, p = 0.001). The RAD51 (rs1801320) variant had no association with colorectal cancer. Conclusions: RASSF1 (rs2073498), SERPINE1 (rs1799889), and EFNA1 (rs12904) variants significantly influence colorectal cancer risk.

15 April 2025 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
YTYuri Giovanna Vanessa Trujillo-Fernández
Yuri Giovanna Vanessa Trujillo-Fernández
DRDalia Elizabeth Rodríguez-Torres
Dalia Elizabeth Rodríguez-Torres
CJCesar de Jesus Tovar Jacome
Cesar de Jesus Tovar Jacome
PBPatricio Barros-Núñez
Patricio Barros-Núñez
MGMiriam Yadira Godínez-Rodríguez
Miriam Yadira Godínez-Rodríguez
MRMonica Alejandra Rosales-Reynoso
Monica Alejandra Rosales-Reynoso
Colorectal cancer (CRC) is the most prevalent type of gastrointestinal cancer. Genetic, epigenetic, and lifestyle factors have been implicated in the development of CRC. Non-coding RNAs such as HOX transcript antisense RNA (HOTAIR) and miR-3117 have been associated with cell proliferation, progression, invasion, and metastasis, as well as poor survival in several cancer types. This study examines the potential association between the HOTAIR (rs920778 T>C) and miR-3117 (rs7512692 C>T and rs4655646 G>A) variants and the clinicopathological features of CRC in Mexican patients. The study included genomic DNA of peripheral blood samples from 557 individuals (296 CRC patients and 261 controls). The variants were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The association was calculated using the odds ratio (OR) test. P-values were adjusted using the Bonferroni test (0.016). Individuals carrying the T/C and C/C genotypes for the HOTAIR rs920778 variant exhibited a higher susceptibility to CRC (OR=1.73, 95% CI: 1.15-2.58, P=0.009 and OR=2.78, 95% CI: 1.74-4.45, P=0.001, respectively). Male patients older than 50 years and carrying the C/C genotype demonstrated an increased susceptibility to developing CRC (OR=2.77, 95% CI: 1.63–4.70, P=0.001). Additionally, C/C genotype carriers exhibited an association with the advanced TNM stage. Furthermore, for the rs7512692 variant of the miR-3117 gene, patients carrying the C/T genotype exhibited increased susceptibility to developing CRC (OR=1.92, 95% CI: 1.35-2.74, P=0.001). Male patients over 50 years of age and carrying the C/T genotype demonstrated increased susceptibility for early TNM stages and tumor location in the colon. The results obtained suggest that the HOTAIR rs920778 and miR-3117 rs7512692 variants play a significant role in colorectal cancer risk.

8 September 2025 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
JRJessica Fabiola Rodriguez-Ortiz
Jessica Fabiola Rodriguez-Ortiz
ASAnilú Margarita Saucedo-Sariñana
Anilú Margarita Saucedo-Sariñana
MRMonica Alejandra Rosales-Reynoso
Monica Alejandra Rosales-Reynoso
JPJanet Soto Padilla
Janet Soto Padilla
RORocio Ortiz-Lopez
Rocio Ortiz-Lopez
PBPatricio Barros-Núñez
Patricio Barros-Núñez
The objective of this study was to evaluate the concentration and integrity index of circulating cell-free DNA (ccf-DNA) as biomarkers for the detection and monitoring of minimal residual disease (MRD) in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Comparison with a validated methodology for the quantification of monoclonal rearrangements of the IGH gene was made. Peripheral blood and bone marrow samples were collected from 10 pediatric patients with B-ALL at diagnosis, remission, and maintenance phases. Total ccf-DNA concentration was estimated using Qubit® fluorometry, and the integrity index was obtained through qPCR amplification of ALU247/ALU115 fragments. Monoclonal rearrangements of the IGH gene were quantified by multiplex PCR and detected by capillary electrophoresis. Results showed that at diagnosis, the mean ccf-DNA concentration was 5,607 ng/mL with an integrity index of 0.38; during remission induction, they were 968 ng/mL and 0.35; and during the maintenance phase, 748 ng/mL and 0.33, respectively. Differences between treatment phases were significant (p=0.02). The reference group had a mean ccf-DNA concentration of 247 ng/mL and an integrity index of 0.20, showing significant differences compared to the patient group (p=0.01). Monoclonality analysis showed significant differences between diagnosis and remission (p=0.022) and between diagnosis and maintenance (p=0.001). Linear regression analysis during treatment demonstrated a similar trend for ccf-DNA concentration and monoclonality. In conclusion, ccf-DNA concentration and integrity index could be useful biomarkers for monitoring MRD in patients with B-ALL, showing comparable efficacy to the detection of monoclonality in the IGH gene.

24 September 2026 in Genes
Verified
Journal Article
Open access
PDF file
CJCesar de Jesus Tovar Jacome
Cesar de Jesus Tovar Jacome
Luis Felipe Jave-SuárezLuis Felipe Jave-Suárez
Luis Felipe Jave-Suárez
Jesús García-GómezJesús García-Gómez
Jesús García-Gómez
Adriana Aguilar-LemarroyAdriana Aguilar-Lemarroy
Adriana Aguilar-Lemarroy
ASAugusto Sarralde-Delgado
Augusto Sarralde-Delgado
MRMonica Alejandra Rosales-Reynoso
Monica Alejandra Rosales-Reynoso
Background/Objectives: Colorectal cancer (CRC) is a leading cause of neoplasia-related morbidity and mortality worldwide and the first cause of cancer death in Mexico, where early detection remains a challenge, and reliable molecular biomarkers could support earlier diagnosis. Transcriptomic signatures for CRC have been published, but different studies arrive at gene lists that barely overlap, and since each study differs in both cohort and analysis, the source of that disagreement cannot be identified. This study aimed to identify a gene set for CRC discrimination whose selection depends neither on how the batch effect is handled nor on the criterion by which candidates are chosen and to validate that set in repositories that took no part in its selection. Methods: The signature was identified in 104 public RNA-seq samples (79 tumor, 25 reference) obtained from six BioProjects of the NCBI Sequence Read Archive and analyzed twice. A functionally anchored route took one representative gene per enriched biological program, ranked by π-value, from a differential expression model including BioProject as a covariate; a regularization route selected genes by their stability under Elastic Net in nested cross-validation over a ComBat-Seq-adjusted matrix. The genes reached by both routes were corroborated in TCGA-COAD, TCGA-READ, and GTEx colon processed by recount3 (n = 1542), with every parameter held fixed, and in the GEO microarray series GSE37364 (the 65 carcinoma and normal-mucosa samples of a 94-sample series), where only the coefficient vector was transferred because the platform differs; they were further examined descriptively in a second adenoma series (GSE89076), published stool RNA-seq, and plasma cell-free RNA. Results: The two routes yielded a seven-gene and a five-gene signature sharing a single gene, RPGRIP1L. Five genes met both criteria: TRIP13, CEMIP, PUS7, RPGRIP1L, and SLC22A3. With every parameter held fixed, the five-gene core reached an AUC of 0.9993 in TCGA/GTEx (sensitivity 0.966, specificity 0.998); with its coefficients transferred and the intercept recalibrated, it reached 0.9737 in GSE37364 (sensitivity 0.926, specificity 0.974). All five were elevated in adenoma relative to normal mucosa in GSE37364, and three of the five reached significance in GSE89076, where only five adenomas were available; all five were overexpressed in published stool RNA-seq of CRC patients. Conclusions: A five-gene core, TRIP13, CEMIP, PUS7, RPGRIP1L, and SLC22A3, discriminates colorectal tumor tissue from non-tumor in repositories external to its selection, with elevation already present in premalignant adenoma. Having been reached by two routes that share neither criterion nor starting point, these five genes are candidates for experimental validation and for evaluation in material accessible without biopsy.